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CD4 + T cell responses were analyzed in transgenic mice expressing a soluble form of murine 
CTLA-4, mCTLA4-H3,1, which blocks the interaction of the T cell activation molecules CD28 
and CTLA-4 with their costimulatory ligands. Consistent with previous reports (Linsley, P. S., 
P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. 
Tepper. 1992. Science (Wash. DC). 257:792), T cell-dependent antibody production was profoundly 
inhibited in mCTLA4-H'y1 transgenic mice immunized with a protein antigen. Surprisingly, 
however, transgenic mice could generate quantitatively and qualitatively normal primary T cell 
responses,  as measured by limiting dilution assays and lymphokine production. In addition, in 
vi r  expansion of antigen-specific T cells after secondary or tertiary immunization was enhanced 
in mCTLA4-H3'I transgenics as compared with normal mice. Although unable to deliver cog- 
nate help to B cells in vivo,  T  cells from mCTLA4-H'y1 transgenic mice were not anergic as 
they could help B cells to produce specific antibodies when adoptively transferred into nude hosts. 
Taken together, these data suggest that the engagement of CD28 and/or CTLA-4 may not be 
required for the induction of T  cell responses,  as is currently understood, but rather for the 
expression of T  cell effector function such as the delivery of T  cell help to B cells. 
S 
timulation of T  cells through the T  cell receptor is by 
itself an insufficient signal to induce T cell proliferation. 
When activated in this manner, T cells enlarge and express 
IL-2 receptors but secrete diminished amounts of IL-2 and 
other lymphokines, fail to proliferate, and become unrespon- 
sive to further antigenic stimulation. To achieve full activa- 
tion, T cells also require a costimulatory signal,  usually pro- 
vided by the APC (reviewed in 1). One accessory molecule 
thought to provide a costimulatory signal to T cells is B7/BB1 
(2-5), which is expressed on dendritic cells and on activated 
B cells, T cells, and macrophages (6-10). B7/BB1 is the ligand 
for two T cell surface molecules, CD28 and CTLA-4. CD28 
is expressed on all murine T  cells and binds B7/BB1 with 
intermediate affinity (11, 12), while CTLA-4 is detectably 
expressed only after T  cells have been activated and binds 
B7/BB1 with high affinity (13,  14). Additional ligands for 
CD28 and CTLA-4, which are distinct from B7/BB1  and 
appear to be predominantly expressed on B cells,  have re- 
cently been described (15-18).  Costimulation through CD28 
provides a potent accessory signal to T  cells that increases 
IL-2 production by stabilizing lymphokine mRNA (19, 20). 
In vivo studies have shown that blocking of CD28-depen- 
dent signaling with a soluble form of CTLA-4 can inhibit 
T cell-dependent antibody production (21), allow long-term 
survival of xenogeneic grafts (22), and delay the rejection of 
allogeneic grafts (23). Although these studies are consistent 
with the predicted role of CD28 costimulation in enhancing 
T cell responses and preventing the induction of anergy, they 
provide little or no direct evidence that soluble CTLA-4 in- 
deed interferes with the generation of T cell responses in vivo, 
or about the precise stage of the response that is affected by 
the treatment. To investigate this question, transgenic mice 
were generated that secrete a soluble form of CTLA-4, mouse 
CTLA4-human yl (mCTLA4-H3,1) 1, which can block the 
interaction of CD28 and/or CTLA-4 with their costimula- 
tory ligands (24). These mCTLA4-H'y1 transgenic mice were 
used to examine the role of CD28-dependent costimulation 
in the induction of T cell and B cell immune responses in vivo. 
Materials  and Methods 
Mice.  mCTLA4-H'y1 transgenic mice were maintained at the 
Basel Institute for Immunology by breeding transgenic males to 
C57BL/6 females (Iffa-Credo, EArbresle, France). Progeny were 
1 Abbreviations used in this  patx'r: mCTLA4-Hq/1, mouse  CTLA4-human'yL 
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of the transgenic product. C57BL/6 nu/nu were obtained from 
Bomholtg~rd  (Ry,  Denmark),  BALB/c  nu/nu  were  from 
Iffa-Credo. 
Antigens  and  Immunizations.  KLH  was  obtained  from 
Calbiochem-Behring Corp. (La Jolla, CA); coupling to DNP was 
performed as previously described (25). Mice were primed i.p. with 
100/~g.  DNP-KLH in alum adjuvant on day 0 and boosted i.p. 
with 100/~g soluble DNP-KLH at 7-14-d intervals. Serum samples 
were taken by tail bleeding and analyzed by ELISA. 
Preparation of Dendritic Cells.  A  modification of the original 
method of Steinman et al. (26) was used. Briefly, spleen cell sus- 
pensions were prepared by digestion with a cocktail of 2.5 mg/ml 
collagenase  (Worthington Biochemical Corp., Freehold, NJ) and 
0.1% DNAse (Sigma Chemical Co., St. Louis, MO) in serum-free 
medium at 37~  for 2  x  40 min; low-density cells were isolated 
by centrifugation over a 60% Percoll gradient (p  =  1.076) and 
the floating fraction was collected. Dendritic cells were enriched 
by differential adherence by incubating cells in medium containing 
1% normal mouse serum (NMS) on 100-mm tissue culture plates 
(Falcon Labware, Oxnard, CA) for 2 h at 37~  removing the nonad- 
herent fraction,  and culturing the remaining cells overnight in 
medium containing 0.5% NMS and 50 #g/ml KLH. On the next 
day floating cells were collected and depleted of contaminating T 
cells and B cells by incubation with 10 #g/ml each of antioThy-1 
(T24; 27) and anti-B220 (6B2; 28) mAb followed by sheep anti-rat 
Dynabeads (Dynal; Oslo, Norway) and magnetic adherence.  The 
resulting population was >70-80% dendritic cells as judged by mor- 
phology and FACS  |  staining (Becton Dickinson & Co., Mountain 
View,  CA) with the dendritic cell-specific  mAb N418 (29). 
Tissue Culture Media.  All cultures were in Iscove's modified 
DMEM additioned with 10% FCS (Boehringer Mannheim, Mann- 
heim, Germany), 2 mM glutamine (Gibco, Paisley, Scotland) 1% 
penicillin-streptomycin (Gibco), and 5  x  10 -5 M  2-ME (Sigma 
Chemical Co.). Human rlL-2 was obtained through the courtesy 
of Dr. F. Sinigaglia  (Hoffmann-La Roche, Basel,  Switzerland). 
Inhibition of  In Vitro Alloresponses by mCTLA4-H71.  Spleen and 
lymph node cell suspensions  from donor mice were pooled and 
depleted of B cells and accessory cells by incubation with sheep 
anti-mouse Dynabeads (Dynal), and magnetic adherence, followed 
by 1-2 h plastic adherence in medium containing 5% FCS. Col- 
lected cells were cultured in triplicate  at 2.5  x  10Vwell in 96-well 
flat bottom microtiter plates (Costar Corp., Cambridge, MA) in 
200/zl total volume, with 2.5  x  105 irradiated allogeneic or syn- 
geneic nu/nu spleen cells that had been preincubated for 45 min 
in graded concentrations of mCTLA4-H71, or mCD40-H71 (30) 
as an isotype-matched control. After 72 h of culture cells were pulsed 
overnight with 1 #Ci  [3H]TdR/well. 
Anti-CD28 Costimutation Assays.  Peripheral T cells from donor 
mice were depleted orB cells and accessory cells as described above, 
and  cultured in  triplicate at  3  x  104 cells/well in  96-well  flat 
bottom microtiter plates coated with graded amounts of anti-CD3 
(31), in the presence or absence of soluble anti-CD28 culture su- 
pernatant (19) at 10% final concentration. After 48 h of culture 
cells were pulsed overnight with  1 #Ci  [3H]TdR/well. 
Limiting Dilutions.  7-10 d after the last immunization, mice 
were killed,  spleen  and draining lymph nodes were pooled and 
depleted of B cells, and other MHC class II-expressing cells by 
incubation with Y-3P monoclonal antibody (32) followed by sheep 
anti-mouse conjugated Dynabeads (Dynal) and magnetic adher- 
ence. The numbers of KLH-specific, 1I.-2 or IL-3-producing T cells 
were determined in a limiting dilution assay as described (25) by 
plating  different  dilutions  of T  cells  on  3  x  104  irradiated 
C57BL/6 nu/nu spleen cells, with or without 50 #g/ml KLH, in 
complete medium in 96-well round bottom microtiter plates (Costar 
Corp.). IL-2 or II.-3 production was assayed by cocultivation with 
the appropriate indicator cell lines. 
IFN-'y Assays.  B-depleted spleen and lymph node cells from 
control and transgenic littermates were cultured at 2  x  10S/well 
in  96-well  flat  bottom  microplates  with  4  x  10  s  irradiated 
C57BL/6 nu/nu spleen cells and various concentrations of KLH; 
the total volume was 200/~1.  Supernatants were harvested after 
72 h of  culture and tested in a sandwich ELISA using mouse recom- 
binant IFN-7 (Genzyme, Cambridge, MA) as a standard.  Capture 
antibody was AN18.17.24 (33), detecting antibody was XGM-D6- 
biotin (34); the reaction was developed with streptavidin-horseradish 
peroxidase  (Southern Biotechnology, Birmingham, AL). 
IL-4 Assays.  Cells from transgenic and control mice were cul- 
tured as detailed  for the IFN-3' assays but in the presence of 10 
U/ml of recombinant human IL-2 (Roche Laboratories, Nutley, NJ); 
after 72 h of incubation plates were irradiated, 100 #1 supernatant 
were removed and replaced with 100 #1 medium containing 104 
IL-4-dependent CT-4S cells (35). Plates were incubated for a fur- 
ther 24 h and pulsed with 1 #Ci [3H]TdR/well for 6 h. Prolifera- 
tion of CT-4S was completely inhibited by an IL-4-specific mono- 
clonal antibody (PharMingen,  San Diego, CA). 
Adoptive Transfer Experiments.  C57BL/6 nu/nu mice were in- 
jected i.v. with 106 purified T  cells from sex-matched  control or 
transgenic mice that had been immunized three times with DNP- 
KLH; 24 h later reconstituted or nonreconstituted nu/nu mice were 
immunized i.p.  with 100/~g DNP-KLH in alum, bled 9 d after 
immunization, and tested for DNP-specific serum IgG by ELISA. 
ELISA.  Plates  coated with  5 /~g/well  DNP-OVA were in- 
cubated with dilutions of test sera for 2 h at room temperature, 
washed, and incubated for a further 2 h with peroxidase-conjugated 
sheep anti-Ig or Sheep anti-IgG (Southern Biotechnology) as indi- 
cated. The reaction was developed by adding ABTS  |  (Boehringer 
Mannheim) and read on an ELISA reader (Multiskan MCC/340; 
Titerteck, Elfab Oy, Finland). 
Results 
T  Cells from mCTLA4-H3'I  Transgenic Mice Are Sensitive 
to Anti-CD28  Costimulation In  Vitro.  Although  immature 
T cells express CD28 (11), T cell development in the thymus 
is reportedly independent of CD28-dependent costimulation 
(36, 37). This would suggest that T  cells in mCTLA4-H3'I 
transgenic mice should  not be developmentally selected to 
be independent of CD28 signaling. Nonetheless, in order to 
test whether this could be the case, peripheral T  cells from 
mCTLA4-H71 transgenic and control mice were tested for 
the ability to mount in vitro primary alloresponses when in 
the presence of soluble CTLA-4 (14,  6). As shown in Fig. 
1 A, addition of mCTLA4-H71 inhibited the in vitro prolifer- 
ative responses to alloantigen of both mCTLA4-H71 trans- 
genic and control T cells; the inhibition was dose dependent 
and followed similar dose responses in both groups of mice. 
A  control construct also bearing the Fc portion of human 
3'1  (mCD40-H3'I)  had  no effect on  the response. 
To further confirm that T cells from mCTLA4-H3"I trans- 
genic mice bear a functional CD28  molecule, T  cells from 
mCTLA4-H3'I transgenic and control mice were also tested 
in an in vitro costimulation assay (19). Purified T  cells from 
either group were stimulated with graded concentrations of 
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Figure  1.  CD28-mediated  signaling  is  functional  in  T  cells  from 
mCTLA4-H3"I  transgenic  mice.  (A)  Inhibition  of primary  MLK by 
mCTLA4-H3,1. Open symbols, control mice; closed  symbols, transgenic mice. 
Proliferation  was measured  in the presence of the indicated  amounts of 
mCTLA4-H3,1 (circles) or of the isotype-matched  control mCD40-H3,1 
(triangles); 100% response was 45,900 cpm and 52,500 cpm for control 
and transgenic mice, respectively. (B) Costimulation of anti-CD3 prolifer- 
ative responses by anti-CD28. Open symbols, control mice; closed symbols, 
transgenic  mice. Anti-CD3-induced proliferation  was tested in the pres- 
ence (trangles) or absence (circles) of anti-CD28. Values represent the mean 
-+  SE of triplicate  cultures. Peripheral T cells from control or transgenic 
mice were isolated and cultured as detailed in Material and Methods:  (A) 
in a primary MLR, on irradiated  allogeneic BALB/c nu/nu  spleen cells 
in the presence of the indicated amounts  of mCTLA4-H3'I or mCD40- 
H3'1; (B) on the indicated amounts of plate-bound  anti-CD3, in the pres- 
ence or absence of 10%  supernatant  from the CD28-specific bybridoma 
37-51. 
plate-bound anti-CD3 in the presence or absence of anti-CD28, 
and their proliferative response measured. T cells from either 
group of mice showed enhanced proliferation  in the presence 
of anti-CD28 (Fig.  1 B), suggesting that the CD28 mole- 
cule is functional in both groups of mice. 
Therefore,  T cells in mCTLA4-Hyl transgenic  mice are 
not CD28 independent,  as their in vitro responses can be 
readily inhibited by the addition  of mCTLA4-H3'I, or en- 
hanced by anti-CD28  cross-linking. 
mCTLA4-Hq/1  Transgenic Mice Have Reduced Antibody Re- 
sponses.  To determine the effect of blocking costimulation 
via CD28 on in vivo immune responses, mCTLA4-H3,1 trans- 
genic and control littermates  were immunized with DNP- 
KLH in alum and analyzed for the ability to generate DNP- 
specific serum antibodies.  Consistent with previous reports 
where a soluble form of CTLA-4 was injected into mice (21), 
mCTLA4-H3'I transgenic mice showed almost undetectable 
primary antibody responses and significantly reduced secondary 
and tertiary antibody responses (Fig. 2). Further analysis of 
the  Ig  isotype of the  specific antibodies  revealed  that  in 
mCTLA4-H3,1 transgenic mice most of the antibodies made 
were of the IgM class, with very little IgG being detected; 
no specific IgG subclass was found to predominate in the re- 
sponse (30). In contrast, control littermates  generated  high 
titers of specific IgG. Therefore,  the levels of mCTLA4-H3,1 
in  transgenic  mice  were sufficient  to  significantly  inhibit 
specific antibody responses, reproducing the phenotype al- 
ready described in mice injected with soluble CTLA-4 (21) 
and  suggesting that  effective in vivo blocking of CTLA- 
4-binding  molecules  had been achieved. 
mCTLA4-H'yl Transgenic Mice Generate Normal or Enhanced 
T  Ceil Responses.  To determine whether  the inability  of 
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DNP-specific antibody response in mCTLA4-Hq,1  transgenic 
mice and control ]ittermates  after immunization with DNP-KLH. Open 
circles, control mice; closed circles, transgenic mice. Transgenic and control 
mice were primed i.p. with 100 #g DNP-KLH in alum adjuvant  on day 
0, and boosted i.p. at the indicated times with 100 #g soluble DNP-KLH. 
Serum samples were taken by tail bleeding and analyzed by ELISA. Values 
represent  mean  _+  SE of five mice per group. 
mCTLA4-H3,1 mice to generate specific antibodies was indeed 
due to a defect in T cell responses, mCTLA4-Hyl transgenic 
and control littermates  were immunized with DNP-KLH 
as described above and tested for the frequency of KLH-specific, 
IL-2- or IL-3-producing T cells in a limiting dilution assay. 
Surprisingly, as shown in Fig. 3, A and B, primary immuni- 
zation with DNP-KLH induced  in both groups of mice a 
three-  to sixfold increase in the number of KLH-specific T 
cells with respect to unimmunized mice; no clear difference 
between transgenics  and  controls was detectable  in either 
numbers of IL-2- or IL-3-producing T  cells, or in T  cell 
proliferation  experiments  (not shown).  This  suggests  that 
in vivo expansion of antigen-specific T cells could occur to 
a comparable degree in control as well as in transgenic  mice, 
presumably due to autocrine production of IL-2 and/or IL-4 
in  vivo,  and  that  the  defect  in  antibody  production  in 
mCTLA4-Hyl transgenic  mice could not be ascribed to a 
defect in T  cell responses. 
T cell responses in mCTLA4-Hqr  transgenic and control 
littermates  were compared also after multiple antigen immu- 
nizations. After one or two boosts with DNP-KLH, control 
mice showed no significant increase in the numbers of KLH- 
specific, IL-2- or IL-3-producing T cells as compared  with 
primary immunization.  In contrast, boosting of transgenic 
mice further increased the numbers of antigen-specific T cells 
by three- to fivefold with respect to primary immunization. 
Thus, mCTLA4-H3,1 transgenic mice not only have no ob- 
vious defect in the ability to generate T cell responses after 
immunization with a protein antigen in vivo, but in fact ap- 
pear to have increased numbers of antigen-spedfic T cells after 
multiple immunizations. 
To test whether the normal T cell responses detected after 
immunization with KLH in adjuvant could also be induced 
using other immunization protocols, mCTLA4-H3'I trans- 
genic and control mice were immunized with KLH-pulsed 
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Figure  3.  KLH-specific 1I.-2 (A) and IL-3 (B) production in mCTLA4- 
H'y1 transgenic mice and control littermates after immunization with DNP- 
KLH. White bars, control mice; hatched bars, transgenic mice. Control and 
transgenic mice were left unimmunized or immunized at 7-14-d intervals 
as in Fig. 2, and killed 7-10 d after the last immunization. Numbers of 
KLH-specific, IL-2-, or IL-3-producing  T cells in B-depleted spleens and 
draining lymph nodes were determined in a limiting dilution assay; numbers 
of cells producing IL-2 or IL-3 in the absence of KLH (m20-50/106  T 
cells) are subtracted.  Values given represent  the arithmetic mean of two 
mice per group; error bars show the deviation  of individual values from 
the mean. 
dendritic cells, a procedure already described to induce efficient 
priming  of T  cell  responses  (38). As  shown  in  Fig. 4, 
mCTLA4-H3,1  transgenic and control littermates responded 
equally well to immunization with KLH-pulsed dendritic 
cells, as comparable numbers of KLH-specific, IL-2-producing 
T  cells were generated by both groups of mice. This sug- 
gests that the antigen presenting function of dendritic cells 
is not sensitive to mCTLA4-Hyl inhibition in vivo, thus 
allowing the normal priming of antigen-specific T cell re- 
sponses. 
rnCTLA4-H3,1  Transgenic Mice Can Generate Both IFN-q/- 
and IL-4-producing T Cells.  The requirement for costimu- 
lation via CD28 is reported to be linked to the Th pheno- 
type of T cell clones. In vitro experiments have shown that 
Thl clones, which produce IL-2, IL-3, IFN-y, and TNF-3, 
require costimulation through CD28 (39). In contrast, Th2 
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Figure 4.  KLH-specific IL-2 production in mCTLA4-H3'I transgenic 
and control littermates  after immunization with KLH-pulsed  dendritic 
cells. White bars, control mice; hatched bars, transgenic mice. Control and 
transgenic mice were immunized i.p. with 6  x  10  s KLH-pulsed dendritic 
cells and sacrificed  9 d after immunization.  Numbers of KLH-specific, IL-2- 
producing  T cells in B-depleted  spleens and draining  lymph nodes were 
determined  in a limiting dilution assay; numbers  of cells producing  IL-2 
in the absence of KLH (m20-50/106  T cells) are subtracted. Values given 
represent  the arithmetic mean of two mice per group; error bars show 
the deviation  of individual  values from the mean. 
clones, which produce IL-3, IL-4, IL-5, and IL-10, report- 
edly do not require signaling through CD28,  and may be 
dependent on other costimulatory signals (40, 41). To evaluate 
the possibility that selective priming of Th2 cells was occur- 
ring in the DNP-KLH immunized mCTLA4-H3,1 transgenic 
mice, responding T cells were tested for the pattern of lym- 
phokines produced. As shown in Fig. 5, A and B, after pri- 
mary immunization, transgenic animals produced more IFN-3, 
but less IL-4 than nontransgenic controls; upon subsequent 
immunizations,  both groups of mice produced comparable 
amounts of IL-4 (Fig. 5 C) but very little or no IFN-y (not 
shown). No secretion of IFN-3, or IL-4 could be detected 
in unimmunized animals of either group under these condi- 
tions. Therefore, IL-4-producing T cells might be more sen- 
sitive than IFN-3,-producing ones  to  the lack of CD28- 
mediated costimulation during priming. Although transgenic 
mice could produce more IFN-3' but less IL-4 upon primary 
immunization, these differences  were not detected in secondary 
or tertiary responses, suggesting  that both sets of Th cells 
were being primed in the mCTLA4-Hyl transgenics. 
T  Cells  in  mCTLA4-Hyl  Transgenic Mice Are  Not 
Anergic.  In vitro and in vivo experiments have shown that 
T  cell recognition of MHC+antigen  in  the  absence of 
costimulatory signals induces a long lasting state of unrespon- 
siveness, even if production of some lymphokines can still 
be detected (reviewed in 1, 42). Even if rather unlikely, it 
was possible that although T cells in the mCTLA4-Hyl trans- 
genics were able to produce lymphokines in vitro (Figs. 3, 
4, and 5), they had been anergized by in vivo recognition 
of antigen in the absence of costimulatory signals. To assess 
whether this was the case, T cells from immunized trans- 
genic and control mice were adoptively transferred into syn- 
geneic nu/nu mice, and tested for the ability to deliver cog- 
nate  help  to  B  ceils. Previous  experiments  have in  fact 
demonstrated that T cells, rendered unresponsive presumably 
by recognition of antigen on costimulator deficient APCs, 
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Figure  5.  Antigen-specific  IFN-3, and  IL-4 
production in mCTLA4-H'yl transgenic mice and 
control littermates after immunization with DNP- 
KLH. Open circles, control mice; closed  circles, trans- 
genic mice; the results of two mice from each group 
are shown. (A) In vitro IFN-3, production after 
primary immunization with 100/~g DNP-KLH 
in alum. Units given correspond to 106 input T 
cells. (B and C) In vitro Ib4 production after pri- 
mary (B) or tertiary (C) immunization with DNP- 
KLH. Responding T cells were cultured at 2  x 
10S/well. 
are unable to help normal B cells when transferred into adoptive 
hosts (43, 44). As shown in Fig. 6, nu/nu mice injected with 
106 purified  T  cells from either  mCTLA4-H'y1  transgenic 
or control litterrnates and immunized with DNP-KLH gener- 
ated significant titers of DNP-specific IgG. Low or no anti- 
body responses were detected in nu/nu mice not injected with 
T  cells (Fig.  6),  or in nu/nu  mice injected with T  cells but 
not  immunized  with DNP-KLH  (not  shown).  Therefore, 
T  cells from transgenic donors appear not to be anergic,  as 
they can help B cells to produce specific antibodies in vivo. 
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Figure 6.  Specific antibody 
production  in  C57BL/6  nu/nu 
mice injected with T cells from 
mCTLA4-H3/1 transgenic  or con- 
trol  littermates and immunized 
with DNP-KLH. C57BL/6 nu/nu 
mice were injected i.v. with 106 
purified T cells from sex-matched 
control  or transgenic mice that 
had been immunized three times 
with DNP-KLH; 24 h later recon- 
stituted or nont~constituted nu/nu 
mice were immunized i.p. with 
100 #g DNP-KLH in alum, bled 
9 d after immunization, and tested 
for DNP-specific serum IgG by 
ELISA. C57BL/6 nu/nu mice injected with T cells but not immunized 
did not generate detectable DNP-specific antibodies (not shown). Values 
given represent the geometric mean of two mice per group, error bars 
show deviation of the individual values from the mean. 
Discussion 
To study the role of the CD28/CTLA-4 T cell surface mol- 
ecules in immune responses, transgenic mice that endogenously 
express a soluble form of mouse CTLA-4,  mCTLA4-H'y1, 
were  generated,  mCTLA4-H3,1  binds  to  a  number  of 
costimulatory surface molecules expressed by various kinds 
of APCs, thereby blocking their ability to interact with their 
natural ligands CD28 and CTLA-4. mCTLA4-Hyl  is a fu- 
sion protein between mouse CTLA-4 and human IgG1 (24); 
its transcription  is driven from the immunoglobulin  heavy 
chain promoter and the protein is secreted as a soluble dimer. 
mCTLA4-Hyl  transgenic  mice  show  no  gross  alterations 
in  T  cell  development  (consistent  with  36,  37)  or  in  the 
numbers of peripheral  T  cells;  their T  cells are sensitive to 
mCTLA4-H3,1 inhibition,  as well as to anti-CD28 costimu- 
lation,  to the same degree as T  cells from normal mice (Fig. 
1).  T  cell-independent  antibody  responses  are  normal  in 
mCTLA4-H'y1 transgenic mice (30), suggesting that expres- 
sion of the transgene  does not  impair the ability of B  cells 
to produce antibodies. Also, mCTLA4-H3,1-mediated cross- 
linking  of Fc3' receptors on transgenic  B  cells is not likely 
to cause defects in B cell responses, as normal and transgenic 
B  cells respond equally well to in vitro  stimulation  with  a 
soluble form  of CD40  ligand  (30). 
mCTLA4-H'y1 is biologically active in vivo, and its binding 
to  B7/BB1 §  cells  such  as  dendritic  cells  in  the  secondary 
lymphoid organs of transgenic mice can be demonstrated by 
histological methods,  mCTLA4-H3,1  is stably expressed in 
the serum of transgenic mice at levels of 10-30/~g/ml;  these 
levels are sufficient to saturate binding in vitro, and are similar 
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CTLA-4 was injected into mice (21), therefore, they are pre- 
sumably sufficient  to achieve blocking in vivo. 
mCTLA4-H3,1 transgenic mice were used to analyze the 
effect of blocking CD28-dependent costimulation on in vivo 
T  cell responses. The results obtained show that  T  cell re- 
sponses specific for protein antigens are easily elicited in trans- 
genic animals  which express the fusion protein  mCTLA4- 
H3,1  (Figs.  3  and 4),  although  the  kinetics of production 
of some lymphokines are somewhat altered (Fig. 5). By adop- 
tive transfer experiments these cells are also not anergic (Fig. 
6). Therefore, it appears that in vivo priming and expansion 
of CD4 § T  cells may take place when CTLA-4 ligands are 
absent, or present in greatly reduced amounts. It should how- 
ever be noted that, although antigen-specific T cells are clearly 
expanded in mCTLA4-H3,1 transgenic mice, implying that 
T  cell priming  has occurred,  detection of normal  levels of 
lymphokines in vitro does not mean  that  such high levels 
are also produced in vivo in the absence of CD28 costimula- 
tion.  In spite of the normal  induction  of T  cell responses, 
specific antibody production is greatly impaired in mCTLA4- 
H3,1 transgenic  mice (Fig. 2), suggesting that soluble CTLA-4 
may selectively interfere with  the effector function,  rather 
than  the  proliferation  and  expansion,  of antigen-specific 
CD4 §  T  cells.  A  phenotype essentially similar  to the one 
of mCTLA4-H3,1 transgenics has recently been described for 
CD28-deficient mice: although in such mice some T cell re- 
sponses are normal,  antibody responses are significantly im- 
paired  (45).  However, as no direct  evaluation of CD4 + T 
cell function  in CD28-deficient  mice was presented,  more 
specific  comparisons  are not possible at  this  time. 
There are several possible explanations for the observed de- 
fect in antibody production together with normal T cell re- 
sponses. The first is that an intrinsic difference may exist be- 
tween  "professional"  APCs,  such  as  dendritic  cells  or 
Langerhans cells, and other APCs such as B cells, in the re- 
quirement for expression of CTLA-4 ligands. Dendritic cells, 
which are the cells primarily responsible for the priming of 
naive T  cells in vivo (38),  may not  require  the expression 
of CTLA-4 ligands,  for example, because they also express 
other costimulatory molecules (46,  47).  That  this may in- 
deed be the case is supported by the observation reported in 
Fig. 4, where injection with  antigen-pulsed  dendritic cells 
is able to induce T  cell responses in mCTLA4-H3,1  trans- 
genics. In contrast, redundant costimulatory signals may be 
absent or limiting on other APCs such as B cells, rendering 
the function of these latter APCs strictly dependent on ex- 
pression of CTLA-4 ligands. Inhibition of the APC function 
of B cells would not be sufficient to affect T  cell expansion 
(25), but would obviously have a drastic effect on T cell-depen- 
dent antibody responses. Alternatively, as already proposed, 
CD28 signaling may be required for the transition from auto~ 
crine to paracrine lymphokine production (20, 48). In such 
an instance,  T  cells would be able to produce levels of lym- 
phokines which are adequate for autocrine T  cell clonal ex- 
pansion even in the absence of CD28 engagement. Such levels 
would however be insufficient for the expression of T helper 
function for B cells,  resulting  in a phenotype of normal T 
cell responses together with defective antibody production. 
In either of these cases, one could hypothesize that a defect 
similar to the one detected in T cell-dependent B cell responses 
might  also be detected in  other  T  cell-dependent  effector 
mechanisms, such as macrophage activation during delayed- 
type hypersensitivity, or help for the generation of CTL re- 
sponses.  Such view might explain the defective transplant re- 
jection detected in other studies, as well as the enhanced im o 
munogenicity  shown by tumors induced to express B7 by 
DNA-mediated gene transfer (49, 50). Experiments are cur- 
rently in progress to precisely define what T-dependent effector 
responses are defective in mCTLA4-Hyl  transgenic  mice. 
One third possibility is that B7 (or other CTLA-4 ligands) 
is a critical signaling molecule for B cells, and that its blocking 
with mCTLA4-Hyl leads to defective B cell responses de- 
spite optimal T cell effector function in vivo. Although this 
possibility cannot be ruled out at the present time, it is not 
consistent with experimental data on the suppressive effects 
of soluble CTLA-4 detected in other systems (23), and is so 
far not  supported by experimental  evidence. 
Our detection of normal T cell responses to a protein an- 
tigen in mCTLA4-H3,1 transgenic mice is in contrast with 
a previous study (21) where in vivo treatment with CTLA4Ig 
could inhibit the generation of SRBC-specific T cell prolifer- 
ative responses in vitro. However, it has been previously shown 
that the presence of SRBC-specific B cells is required to dem- 
onstrate proliferative T cell responses to SRBC in vitro (51). 
Because B cell responses are defective in mice treated with 
CTLA4Ig, the inability to demonstrate a proliferative response 
could be due to the lack of specific B cells in vitro,  rather 
than  to a failure to prime  specific  T  cells  in vivo. 
It could be argued that the levels of serum mCTLA4-Hyl 
in these transgenic mice are not sufficient to effectively block 
the CTLA-4 ligands. This is unlikely to be the case, as other 
studies that used serum levels of soluble CTLA-4 similar or 
lower than the ones reported here were able to obtain long 
term acceptance of xenogeneic transplants  (22)  and induce 
suppression of antibody responses (21);  a completely com- 
parable degree of suppression of antibody responses was de- 
tected in the present study as well. We cannot, however, rule 
out the possibility that complete blocking may not be achieved 
by using soluble CTLA-4. For example, expression of B7/BB1 
on various APCs can be upregulated after interaction with 
T cells (3, 52). It could then be that CTLA-4 ligands, newly 
expressed in the intercellular space during T cell-APC inter- 
action,  are not available  to mCTLA4-H3,1 present in solu- 
tion. The observation that antigen-pulsed dendritic cells are 
effective in inducing T cell responses in mCTLA4-H'y1 trans- 
genic mice makes this possibility less likely. Splenic dendritic 
cells, such as the ones used in the present study, express levels 
of CTLA-4 ligands that are significantly higher than the ones 
detectable on their precursors,  epidermal Langerhans  cells (6). 
Such ligands  should be readily available  to mCTLA4-Hyl 
in  solution when dendritic  cells  are injected. 
The mCTLA4-H'y1 transgenic mice generate normal pri- 
mary  T  cell  responses,  and  paradoxically  show  increased 
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tions. A  trivial explanation for this finding might be that 
impaired antibody responses  in the transgenics lead to less 
efficient clearance of antigen, with more antigen available for 
the in vivo expansion of T cells. Alternatively, the regulation 
of T cell clonal expansion may be altered in these mice. The 
recent  observation that  activated T  cells express  CTLA-4 
ligands (9, 10, 15, and P. Lane, unpublished observation) and 
efficiently act as APCs may explain this phenomenon, since 
T  cells expressing costimulatory molecules may be able to 
prime regulatory CD8 § T  cells, which then control their 
in vivo clonal expansion. This mechanism would be inhibited 
in mCTLA4-Hyl transgenic mice, where CTLA-4 ligands 
are blocked. A third possibility is that, in intact mice, T cell 
clonal expansion is regulated by the availability  of antigen 
on different kinds of APCs, with some APCs inducing ex- 
pansion, and others maintenance of clone size. Blocking of 
CTLA-4 ligands with mCTLA4-H'y1 may then selectively 
interfere with some (maintenance) but not others (expansion) 
of these signals, leading to abnormal T cell proliferation in 
vivo. For example, by allowing production of higher levels 
of IL-2 (20, 48), CD28 signaling may indirectly cause apop- 
tosis of antigen stimulated T cells (53) and thus control clonal 
expansion. Finally, it is possible that mCTLA4-H',/1 may bind 
preferentially to some of its ligands, while its affinity  for others 
may be too low to allow efficient blocking. The net effect 
of soluble CTLA-4 on an immune response would then de- 
pend on its relative affinity for each of these ligands, on the 
pattern of expression  of these ligands on different cells, and 
on the differential signals transmitted by its receptors (CD28 
vs.  CTLA-4) to the responding T  ceils. 
In conclusion, the present data show that T cell responses 
for a protein antigen are not impaired in mCTLA4-H'y1 trans- 
genic mice, and offer alternatives  to explain the defect in an- 
tibody responses detected after injection of soluble CTLA-4 
in vivo. This is relevant  for understanding whether soluble 
forms of CTLA-4 could be exploited to manipulate in vivo 
immune responses. 
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